C12Y 114/11029
Hypoxia-inducible factor-proline dioxygenase
Official title: Hypoxia-inducible factor-proline dioxygenase (1.14.11.29)
C12Y114/11029 (Hypoxia-inducible factor-proline dioxygenase) appears on 1 US grants and 6 published applications in this corpus.
Search patents in C12Y- Granted patents
- 1
- Published applications
- 6
- Assignees
- 8
- Inventors
- 20
- Latest grant
- 27 Nov 2012
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 1 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Therapeutic agent for treating hif-1alpha-mediated diseases by inhibiting arel1 and restoring phd2 activity7 May 2026US 2026/0125685 A1Biochemgen Inc.
- Biomarker pairs and triplets for predicting preterm birth8 Aug 2024US 2024/0264170 A1Sera Prognostics, Inc.
- Proline hydroxylation primes protein kinases for autophosphorylation and activation4 May 2023US 2023/0138177 A1The Trustees of Columbia University in the City of New York
- Targeting egln1 in cancer24 Mar 2022US 2022/0090083 A1Dana-Farber Cancer Institute, Inc.
- Pharmaceutical composition for cancer prevention and treatment, containing ndrg3 expression or activity inhibitor as active ingredient, or ndrg3 protein-specific antibody and use thereof26 Oct 2017US 2017/0306047 A1Korea Research Institute of Bioscience and Biotechnology
Most cited
By later US patents